FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308136697> ?p ?o ?g. }

• W4308136697 endingPage "A545" @default.
• W4308136697 startingPage "A545" @default.
• W4308136697 abstract "Abstract Objective Cushing's disease (CD) is a debilitating disorder of chronic hypercortisolism. Assessment of 24h mean urinary free cortisol (mUFC) and late-night salivary cortisol (LNSC) is recommended for screening and monitoring treatment response. In the published core period of the Phase III, LINC 3 study (NCT02180217), osilodrostat therapy (a potent oral 11β-hydroxylase inhibitor) produced rapid, sustained reductions in both mUFC and LNSC alongside improvements in clinical signs of hypercortisolism and health-related quality of life (HRQoL) in patients with CD. Here we explored cardiovascular/metabolic-related parameters, physical features and HRQoL according to mUFC and/or LNSC control. Methods LINC 3 (core period) enrolled 137 adults with CD and mUFC &gt;1.5x upper limit of normal (ULN), who received open-label osilodrostat up to 48-week (W) (starting dose: 2 mg twice daily [bid]; maximum: 30 mg bid); eligible patients were randomized in an 8W placebo-controlled, withdrawal period (W26–34). mUFC (three sample average; normal 11–138 nmol/24h [4–‍50 µg/24h]) and LNSC (single sample; normal ≤2.5 nmol/L) were assessed centrally by liquid chromatography-tandem mass spectrometry. Cardiovascular/metabolic-related parameters, physical features (rating: 0=absent;1=mild;2=moderate;3=severe), CushingQoL and Beck Depression Inventory-II (BDI-II) scores were also evaluated. Data were recorded at baseline, regularly throughout, and at W48. Analyses are presented for patients with both mUFC and LNSC assessments, defined as: both mUFC+LNSC controlled (mUFC≤ULN+LNSC≤ULN), only mUFC controlled (mUFC≤ULN+LNSC&gt;ULN), only LNSC controlled (mUFC&gt;ULN+LNSC≤ULN) and both mUFC+LNSC uncontrolled (mUFC&gt;ULN+LNSC&gt;ULN). Results Of evaluable patients at baseline (n=87), 74 (85.1%) had both mUFC+LNSC uncontrolled. At W48, 38 patients (54.3%) had both mUFC+LNSC controlled, 21 (30.0%) had only mUFC controlled, 3 (4.3%) had only LNSC controlled, and 8 (11.4%) had both mUFC+LNSC uncontrolled. Patients with both mUFC+LNSC controlled had generally greater mean improvements from baseline to W48 in cardiovascular/metabolic-related parameters than those with only mUFC or LNSC controlled or both mUFC+LNSC uncontrolled, respectively: weight, –5.9, –3.3, –2.2 and –‍3.8 kg; systolic blood pressure, –14.4, –8.0, –7.4, –3.0 mmHg; diastolic blood pressure, –‍8.6, –4.8, –8.2, –4.0 mmHg; fasting plasma glucose, –16.9, –4.8, –15.0, –11.0 mg/dL; and HbA1c, –0.4, –0.3, –0.9, –0.0%. CushingQoL/BDI-II scores improved from baseline to W48 irrespective of mUFC and/or LNSC control. The proportion of patients with improved physical manifestations of hypercortisolism (facial rubor, striae, fat pads, bruising, hirsutism [females], muscle atrophy) was greatest in patients with both mUFC+LNSC controlled or only mUFC controlled. Discussion At W48, over half the evaluable patients had both mUFC+LNSC controlled following osilodrostat treatment. Improvements in clinical signs of hypercortisolism and HRQoL occurred irrespective of mUFC and/or LNSC control; however, for some clinical outcomes, improvements were greater in patients with both mUFC+LNSC controlled. Findings are limited by small patient numbers in some groups. mUFC and LNSC are complementary parameters used to assess disease control and patients with both mUFC+LNSC controlled have better outcomes. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m." @default.
• W4308136697 created "2022-11-08" @default.
• W4308136697 creator A5001744820 @default.
• W4308136697 creator A5012064746 @default.
• W4308136697 creator A5021628357 @default.
• W4308136697 creator A5022321201 @default.
• W4308136697 creator A5040710891 @default.
• W4308136697 creator A5045002153 @default.
• W4308136697 creator A5055037280 @default.
• W4308136697 creator A5063936702 @default.
• W4308136697 creator A5076292783 @default.
• W4308136697 date "2022-11-01" @default.
• W4308136697 modified "2023-10-07" @default.
• W4308136697 title "PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat" @default.
• W4308136697 doi "https://doi.org/10.1210/jendso/bvac150.1133" @default.
• W4308136697 hasPublicationYear "2022" @default.
• W4308136697 type Work @default.
• W4308136697 citedByCount "0" @default.
• W4308136697 crossrefType "journal-article" @default.
• W4308136697 hasAuthorship W4308136697A5001744820 @default.
• W4308136697 hasAuthorship W4308136697A5012064746 @default.
• W4308136697 hasAuthorship W4308136697A5021628357 @default.
• W4308136697 hasAuthorship W4308136697A5022321201 @default.
• W4308136697 hasAuthorship W4308136697A5040710891 @default.
• W4308136697 hasAuthorship W4308136697A5045002153 @default.
• W4308136697 hasAuthorship W4308136697A5055037280 @default.
• W4308136697 hasAuthorship W4308136697A5063936702 @default.
• W4308136697 hasAuthorship W4308136697A5076292783 @default.
• W4308136697 hasBestOaLocation W43081366971 @default.
• W4308136697 hasConcept C118552586 @default.
• W4308136697 hasConcept C126322002 @default.
• W4308136697 hasConcept C134018914 @default.
• W4308136697 hasConcept C139719470 @default.
• W4308136697 hasConcept C142724271 @default.
• W4308136697 hasConcept C159110408 @default.
• W4308136697 hasConcept C162324750 @default.
• W4308136697 hasConcept C187212893 @default.
• W4308136697 hasConcept C204787440 @default.
• W4308136697 hasConcept C27081682 @default.
• W4308136697 hasConcept C2776810848 @default.
• W4308136697 hasConcept C2776867660 @default.
• W4308136697 hasConcept C2779134260 @default.
• W4308136697 hasConcept C2779631380 @default.
• W4308136697 hasConcept C2779951463 @default.
• W4308136697 hasConcept C558461103 @default.
• W4308136697 hasConcept C71924100 @default.
• W4308136697 hasConcept C77411442 @default.
• W4308136697 hasConcept C90924648 @default.
• W4308136697 hasConceptScore W4308136697C118552586 @default.
• W4308136697 hasConceptScore W4308136697C126322002 @default.
• W4308136697 hasConceptScore W4308136697C134018914 @default.
• W4308136697 hasConceptScore W4308136697C139719470 @default.
• W4308136697 hasConceptScore W4308136697C142724271 @default.
• W4308136697 hasConceptScore W4308136697C159110408 @default.
• W4308136697 hasConceptScore W4308136697C162324750 @default.
• W4308136697 hasConceptScore W4308136697C187212893 @default.
• W4308136697 hasConceptScore W4308136697C204787440 @default.
• W4308136697 hasConceptScore W4308136697C27081682 @default.
• W4308136697 hasConceptScore W4308136697C2776810848 @default.
• W4308136697 hasConceptScore W4308136697C2776867660 @default.
• W4308136697 hasConceptScore W4308136697C2779134260 @default.
• W4308136697 hasConceptScore W4308136697C2779631380 @default.
• W4308136697 hasConceptScore W4308136697C2779951463 @default.
• W4308136697 hasConceptScore W4308136697C558461103 @default.
• W4308136697 hasConceptScore W4308136697C71924100 @default.
• W4308136697 hasConceptScore W4308136697C77411442 @default.
• W4308136697 hasConceptScore W4308136697C90924648 @default.
• W4308136697 hasIssue "Supplement_1" @default.
• W4308136697 hasLocation W43081366971 @default.
• W4308136697 hasLocation W43081366972 @default.
• W4308136697 hasOpenAccess W4308136697 @default.
• W4308136697 hasPrimaryLocation W43081366971 @default.
• W4308136697 hasRelatedWork W1988743459 @default.
• W4308136697 hasRelatedWork W2020423578 @default.
• W4308136697 hasRelatedWork W2036057958 @default.
• W4308136697 hasRelatedWork W2037150225 @default.
• W4308136697 hasRelatedWork W2069848618 @default.
• W4308136697 hasRelatedWork W2075320018 @default.
• W4308136697 hasRelatedWork W2077667918 @default.
• W4308136697 hasRelatedWork W2158083719 @default.
• W4308136697 hasRelatedWork W2164206102 @default.
• W4308136697 hasRelatedWork W2165534557 @default.
• W4308136697 hasVolume "6" @default.
• W4308136697 isParatext "false" @default.
• W4308136697 isRetracted "false" @default.
• W4308136697 workType "article" @default.